Nutrition and depression: A review of the evidence

References

• Adams P. B., Lawson S., Sanigorski A., Sinclair A. J. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996; 31(Suppl.)S157–S161
   PubMed Web of Science ®Google Scholar
• Alino J. J., Gutierrez J. L., Iglesias M. L. 5-hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study. International Pharmacopsychiatry 1976; 11: 8–15
   Google Scholar
• Bottiglieri T., Laundy M., Crellin R., Toone B. K., Carney M. W. P., Reynolds E. H. Homocysteine, folate, methylation, and monoamine metabolism in depression. Journal of Neurological Neurosurgery and Psychiatry 2000; 69: 228–232
   PubMed Web of Science ®Google Scholar
• Bourre J. M. Roles of unsaturated fatty acids (especially omega 3 fatty acids) in the brain at various ages and during ageing. Journal of Nutrition in Health and Ageing 2004; 8: 163–174
   PubMedGoogle Scholar
• Coppen A., Bailey J. Enhancement of antidepressant action of fluoxetine by folic acid: A randomised controlled trial. Journal of Affective Disorders 2000; 60: 121–130
   PubMed Web of Science ®Google Scholar
• Department of Health. Report of the Panel on Dietary Reference Values of the Committee on Medical Aspects of Food Policy (COMA). Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. Report on Health and Social Subjects 41. HMSO, London 1991
   Google Scholar
• Edwards R., Peet M., Shay J., Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. Journal of Affective Disorders 1998; 48: 149–155
   PubMed Web of Science ®Google Scholar
• Fava M., Borus J. S., Alpert J. E. Folate, B12 and homocysteine in major depressive disorder. American Journal of Psychiatry 1997; 154: 426–428
   PubMed Web of Science ®Google Scholar
• Godfrey P. S., Toone B. K., Carney M. W., Flynn T. G., Bottiglieri T., Laudy M., Chanarin I., Reynold E. H. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990; 336: 392–395
   PubMed Web of Science ®Google Scholar
• Harbige L. S. Fatty acids, the immune response and auto-immunity: A question of n-6 essentiality and the balance between n-6 and n-3. Lipids 2003; 3: 323–341
   Google Scholar
• Hibbeln J. R. Fish consumption and major depression [letter]. Lancet 1998; 351: 1213
   PubMed Web of Science ®Google Scholar
• Hintikka J., Tolmunen T., Tanskanen A., Viinamaki H. High vitamin B12 level and good treatment outcome may be associated in major depressive disorder. Biomedical Central Psychiatry 2003; 3: 17
   Google Scholar
• Maes M., D'Haese P. C., Scharpe S., D'Hondt P. D., Cosyns P., De Broe M. E. Hypozincaemia in depression. Journal of Affective Disorders 1994; 31: 135–140
   PubMed Web of Science ®Google Scholar
• Maes M., Wauters A., Verkerk R., Demedts P., Neels H., Van Gastel A., Cosyns P., Scharpe S., Desnyder R. Lower serum L-tryptophan availability in depression as a marker of a more generalised disorder in protein metabolism. Neuropsychopharmacology 1996; 15: 243–251
   PubMed Web of Science ®Google Scholar
• Maes M., Smith R., Christophe A., Cosyns P., Desnyder R., Meltzer H. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. Journal of Affective Disorders 1996; 38: 35–46
   PubMed Web of Science ®Google Scholar
• Maes M., Vandoolaeghe E., Neels H., Demedts P., Wauters A., Meltzer D., Altamura C., Desnyder R. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response to that illness. Biological Psychiatry 1997; 42: 349–358
   PubMed Web of Science ®Google Scholar
• Mamalakis G., Kiriakakis M., Tsibinos G., Kafatos A. Depression and adipose polyunsaturated fatty acids in the survivors of the seven countries study population of Crete. Prostaglandins, Leukotrienes and Essential Fatty Acids 2003; 70: 495–501
   Google Scholar
• Marangell L. B., Martinez J. M., Zboyan B. A., Seung Kim H. F., Puryear L. J. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. American Journal of Psychiatry 2003; 160: 996–998
   PubMed Web of Science ®Google Scholar
• Marchiolli R., Barzi F., Bomba E., Chieffo C., Di Gregorio D., Di Mascio R., Franzosi M. G., Geraci E., Levantesi G., Maggioni A. P., Mantini L., Marfisi R. M., Mastroguiseppe G., Minnini N., Nicolosi G. L., Santini M., Schweiger C., Tavazzi L., Tognoni G., Tucci C., Valgussa F., GISSI Preventione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarct Miocardio (GISSI)-Prevenzione. Circulation 2002; 105: 1897–1903
   Google Scholar
• Murray O., Lopez A. D. Global mortality, disability and the contribution of risk factors. Global burden of disease study. Lancet 1997; 349: 1436–1442
   PubMed Web of Science ®Google Scholar
• Nardini M., De Stefano R., Iannucecelli M., Borghesi R., Battistini N. Treatment of depression with L-5-hydroxytryphtophan combined with chlorimipramine, a double-blind study. International Journal Clinical Phamacology Research 1983; 3: 239–250
   Google Scholar
• Nehmets B., Stahl Z., Belmaker R. H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry 2002; 159: 477–479
   Google Scholar
• NICE. Nice guidelines to improve the treatment and care of people with depression and anxiety. 2004, www.nice.org.uk/pdf/2004_50_launchdepressionanxiety.pdf
   Google Scholar
• Nowak G., Szewczyk B. Mechanisms contributing to antidepressant zinc actions. Polish Journal of Pharmacology 2002; 54: 587–592
   Google Scholar
• Nowak G., Siwek M., Dudek D., Zieba A., Pilc A. Effect of zinc supplementation on antidepressant therapy in unipolar depression: A preliminary placebo-controlled study. Polish Journal of Pharmacology 2003; 55: 1143–1147
   PubMedGoogle Scholar
• Passeri M., Cucionotta D., Abate G., Senin U., Ventura S., Stramba B. M., Diana R., La Greca P., Le Grazie C. Oral 5-methultetrahydrofolate in senile organic mental disorders with depression: results of a double-blind multicenter study. Ageing 1993; 5: 63–71
   PubMedGoogle Scholar
• Passeri M., Ventura S., Abate G., Cucionotta D., Senin U., Stramba B. M., Diana R. Oral 5-methultetrahydrofolate (MTHF) in depressed associated with senile organic mental disorders (OMDs): a double-blind multicenter study vs. trazone (TRZ). European Journal of Clinical Investigation 1991; 21(2 Pt II)24
   Google Scholar
• Peet M., Murphy B., Shay J., Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biological Psychiatry 1998; 43: 315–319
   PubMed Web of Science ®Google Scholar
• Peet M., Horrobin D. F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Archives of General Psychiatry 2002; 59: 913–919
   PubMed Web of Science ®Google Scholar
• Peet M., Bennett C. N. Relationship between brain lipids, depression and suicide. Phospholipid spectrum disorder in psychiatry and neurology2nd edn, M. Peet, I. Glen, D. F. Horrobin. Marius Press, Carnforth 2003; 403–408
   Google Scholar
• Peet M. Nutrition and depression. Northern Centre for Mental Health, Durham 2004
   Google Scholar
• Quadbeck H., Lehmann E., Tegeler J. Comparison of the antidepressant effect of tryptophan, tryptophan/5-hydroxytryptophan combination and nomifensine. Neuropsychobiology 1984; 11: 111–114
   Google Scholar
• Richardson A. J. The importance of omega-3 fatty acids for behaviour, cognition and mood. Scandinavian Journal of Nutrition 2003; 4: 92–98
   Google Scholar
• Rousseau J. J. Effects of levo-5-hydroxytryptophan on depression and neuropsychic performance: a doubleblind placebo-controlled clinical trial in elderly patients. Clinical Therapeutics 1987; 9: 267–272
   Google Scholar
• Sandsead H., Fredercikson C. J., Penland J. G. History of zinc related to brain function. Journal of Nutrition 2000; 130: 496S–502S
   Google Scholar
• Shaw K., Turner J., Del Mar C. Tryptophan and 5-Hydroxytryptophan for depression (Cochrane Review). The Cochrane Library. John Wiley and Sons, Chichester 2004, Issue 3
   Google Scholar
• SIGN. SIGN 50: A Guideline Developer's Handbook. 2004, www.sign.ac.uk/guidelines/fulltext/50/section6.html
   Google Scholar
• Singleton N., Bumpstead R., O'Brien M., Lee A., Meltzer H. Psychiatric morbidity among adults living in private households in Great Britain: Summary Report. The Office for National Statistics, London 2000
   Google Scholar
• Smith K. A., Fairburn C. G., Cowen P. J. Relapse of depression after rapid depletion of tryptophan. The Lancet 1997; 349: 915–919
   PubMed Web of Science ®Google Scholar
• Su K. P., Huang S. Y., Chiu C. C., Shen W. W. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. European Neuropsychopharmacology 2003; 13: 267–271
   PubMed Web of Science ®Google Scholar
• Tamminga C. A., Nemeroff C. B., Blakely R. D., Brady L., Carter C. S., Davis K. L., Dingledine R., Gorman J. M., Grigoriadis D. E., Henderson D. C., Innis R. B., Killen J., Laughren T. P., McDonald W. M., Murphy G. M., Paul S. M., Rudorfer M. V., Sausville E., Schtzberg A. F., Scolnick E. M., Suppes T. Developing novel treatments for mood disorders: Accelerating recovery. Society of Biological Psychiatry 2002; 52: 589–609
   PubMed Web of Science ®Google Scholar
• Taylor M. J., Carney S., Geddes J., Goodwin G. Folate for depressive disorders (Cochrane Review). The Cochrane Library, Issue 4. John Wiley and Sons, Ltd., Chichester 2004
   Google Scholar
• Thomson J., Rankin H., Ashcroft G., Yates C., McQueen J., Cummings S. The treatment of depression in general practice: A comparison of L-tryptophan, amytriptyline, and a combination of L-tryptophan and amytriptylin with placebo. Psychological Medicine 1992; 12: 741–751
   Google Scholar
• Turner E. H., Loftis J. M., Blackwell A. D. Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology and Therapeutics 2006; 109: 325–338
   PubMed Web of Science ®Google Scholar
• Van Praag J., Korf J., Dols L., Scut T. A pilot study of the predictive value of the probenecid test in the application of 5-hydroxytryptophan as antidepressant. Psychopharmacology 1972; 25: 14–21
   PubMed Web of Science ®Google Scholar
• Van Praag H. M., de Hahn S. Chemoprophylaxis of depressions. An attempt to compare lithium with 5-hydroxytryptophan. Acta Psychiatric Scandinavia 1981; Supplement 290: 191–201
   Google Scholar